Sevil Ceyhan Doğan, Mansur Kayataş, Mustafa Dinler

HEMODİYALİZ HASTALARINDA FİBROMİYALJİ SENDROMU PREVALANSI VE YAŞAM KALİTESİNE ETKİSİ

Amaç: Bu çalışmada, hemodiyaliz hastalarında fibromiyalji sendromu (FM) prevalansını ve bu sendromun cinsiyet, yaş, hemodiyaliz süresi veya diğer laboratuvar parametreleri ile ilişkili olup olmadığını değerlendirdik. Yöntem: Çalışmaya, hemodiyaliz tedavisi alan kronik böbrek hastalığı (KBH) olan 248 hasta dahil edilmiştir. Hastalar, Amerikan Romatoloji Derneği (ACR) 2010 FM tanı kriterlerine göre FM olan 33 bireyden oluşan hasta grubu ve FM olmayan 215 bireyden oluşan hasta grubu olarak ikiye ayrıldı. Hastaların yaşam kalitelerini değerlendirmek için Short Form-36 (SF-36) ve Kidney Disease Quality of Life-36 (KDQOL-36) kullanıldı. Ayrıca FM olan hastalarda fonksiyonel durumu ölçmek için Fibromiyalgia İmpact Questionnaire (FIQ) kullanıldı. Hastaların sosyodemografik verileri, laboratuvar parametreleri ve diyaliz yeterliliği göstergesi olan Kt/V değerleri kaydedildi. Bulgular: Çalışmaya katılan bireylerin 33’ünde (%13,3) FM saptandı. FM tanılı 33 hastanın hepsi kadındı. SF-36 ve KDQOL-36 tüm alt parametreleri yönünden karşılaştırıldığında FM olan grupta, FM olmayan gruba göre yaşam kalitesi anlamlı olarak daha düşüktü (p0,05). Diğer yandan hemodiyaliz tedavisi alan hastalarda ileri yaş, kadın cinsiyet, sistemik hastalık ve/veya hepatit B ve C enfeksiyonu varlığında FM sıklığı anlamlı olarak daha fazlaydı (p

PREVALENCE OF FIBROMYALGIA SYNDROME AND ITS EFFECT ON QUALITY OF LIFE IN HEMODIALYSIS PATIENTS

Objective: We evaluated the prevalence of fibromyalgia syndrome (FM) in hemodialysis patients and whether this syndrome was associated withgender, age, duration of hemodialysis, or other laboratory parameters.Methods: The study included 248 patients with chronic kidney disease (CKD) undergoing hemodialysis. The patients were stratified into twogroups: patients with FM based on the 2010 American College of Rheumatology diagnostic criteria and patients not meeting these criteria withoutFM. Quality of life (QOL) was assessed using the Short Form-36 (SF-36) and Kidney Disease Quality of Life-36 (KDQOL-36) questionnaires.Sociodemographic data, laboratory parameters and a marker for adequacy of hemodialysis (Kt/V) were recorded.Results: FM was detected in 33/248 (13.3%) of patients included. All patients diagnosed as FM were female. When all sub-parameters of SF-36 andKDQOL-36 were compared, QOL was lower in the FM group compared to patients without FM (p0.05). FM frequency was higher in cases ofadvanced age, presence of systemic disease and/or hepatitis B and C infection in patients undergoing hemodialysis (p

PDF

___

1. Bigatti SM, Hernandez AM, Cronan TA, et al. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum. 2008;59(7):961-7. doi: 10.1002/art.23828
2. Çapacı K, Hepgüler S. Fibromiyalji Sendromu Etiyopatogenez. Ege Fiziksel Tıp ve Rehabilitasyon Dergisi. 1998;4:219-25.
3. Ozelsancak R, Doruk Analan P, Leblebici B. Factors Associated with Fibromyalgia Syndrome in Peritoneal Dialysis Patients. Physiother Can. 2019;71(1):77-81. doi: 10.3138/ptc.2017-45.ep
4. Chakrabarty S, Zoorob R. Fibromyalgia. Am Fam Physician. 2007;76(2):247-54.
5. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-55. doi: 10.1001/jama.2014.3266.
6. Topbas M, Cakirbay H, Gulec H, et al. The prevalence of fibromyalgia in women aged 20-64 in Turkey. Scand J Rheumatol. 2005;34(2):140-4. doi: 10.1080/03009740510026337
7. Beyazova M, Gökçe Kutsal Y. Fiziksel Tıp ve Rehabilitasyon. Ankara: Güneş Kitapevi; 2011;2365-74.
8. Süleymanlar G. Kronik Böbrek Hastalığı ve Yetmezliği: Tanımı, Evreleri ve Epidemiyolojisi. Turkiye Klinikleri J Int Med Sci. 2007;3(38):1-7
9. Bardin T. Musculoskeletal manifestations of chronic renal failure. Curr Opin Rheumatol. 2003;15:48-54. doi: 10.1097/00002281-200301000-00009.
10. Ferrari R. Rheumatologic manifestations of renal disease. Curr Opin Rheumatol. 1996;8:71-6. doi: 10.1097/BOR.0b013e32831ca5c5.
11. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600-10. doi: 10.1002/acr.20140.
12. Yücetürk TE, Yücel AE, Yücetürk H, et al. Fibromyalgia: its prevalence in haemodialysis patients and its relationships with clinical and laboratory parameters. Nephrol Dial Transplant. 2005;20:2485-8. doi.org/10.1093/ndt/gfi028
13. Couto CI, Natour J, Carvalho AB. Fibromyalgia: Its prevalence and impact on the quality of life on a hemodialyzed population. Hemodial Int. 2008;12:66-72. doi: 10.1111/j.1542-4758.2008.00243.x.
14. Samimagham H, Haghighi A, Tayebi M, et al. Prevalence of fibromyalgia in hemodialysis patients. Iran J Kidney Dis. 2014;8:236–9.
15. Leblebici B, Özelsancak R, Yılmaz EE ve ark. Fibromyalgia syndrome in Turkish hemodialysis patients. Hemodial Int. 2016;20(1):106–10. doi: 10.1111/hdi.12332.
16. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19-28. doi: 10.1002/art.1780380104.
17. Türkiye 2018 Yılı Ulusal Nefroloji, Diyaliz ve Transplantasyon Kayıt Sistemi Raporu. Türk Nefroloji Derneği 2018.
18. United States Renal Data System. 2019 Annual Data Report. https://www.usrds.org/annual-data-report/ access date 10.10.2020.
19. White KP, Speechley M, Harth M, et al. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol. 1999;26(7):1570-6.
20. Okifuji A, Bradshaw DH, Olson C. Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clin Rheumatol. 2009;28(4):475-8. doi: 10.1007/s10067-009-1094-2.
21. Bennet RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC musculoskeletal disorders. 2007;8:27;1-11. doi: 10.1186/1471-2474-8-27.
22. Yanmaz MN, Mert M, Korkmaz M. The prevalence of fibromyalgia syndrome in a group of patients with diabetes mellitus. Rheumatol Int. 2012;32(4):871-4. doi: 10.1007/s00296-010-1618-8.
23. Tishler M, Smorodin T, Vazina-Amit M, et al. Fibromyalgia in diabetes mellitus. Rheumatol Int. 2003;23(4):171-3. doi: 10.1007/s00296-002-0279-7.
24. Su CH, Chen JH, Lan JL, et al. Increased Risk of Coronary Heart Disease in Patients with Primary Fibromyalgia and Those with Concomitant Comorbidity-A Taiwanese Population-Based Cohort Study. PloS one. 2015;10(9):1-13. doi: 10.1371/journal.pone.0137137.
25. Tsai PS, Fan YC, Huang CJ. Fibromyalgia is associated with coronary heart disease: a population-based cohort study. Reg Anesth Pain Med. 2015;40(1):37-42. doi: 10.1097/AAP.0000000000000190.
26. Espinosa JR, Diaz-Lopez C, Guinot M, et al. Thyroid dysfunction in women with suspected fibromyalgia. Reumatol Clin. 2006:2(2):70-7. doi: 10.1016/S1699-258X(06)73025-X.
27. Swezey RL, Adams J. Fibromyalgia: a risk factor for osteoporosis. J Rheumatol. 1999;26(12):2642-4.
28. Demiral Y, Ergor G, Unal B, et al. Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health. 2006;6:247. doi: 10.1186/1471-2458-6-247.